The BPM Vision doesn't actually work with Withings' Cardio Check-Up—you need an ECG-enabled Withings tracker, like the ...

Pfizer (PFE)-backed Priovant Therapeutics wins U.S. FDA's priority review for skin disorder therapy with a targeted action date in Q3 2026. Read more here.

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Driving global innovation through precision sensing technology, intelligent data integration, and sustainable water ...

Anifrolumab yielded positive outcomes, including remission in 26% of patients, at 6 months across a real-word, multicenter cohort of patients with systemic lupus erythematosus, according to data ...

New V-Class luxury MPV launched in India Offered in the extra-long wheelbase configuration Gets both petrol & diesel engine options Mercedes-Benz India has reintroduced the V-Class in India at an ...

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

The Winter El Prix 2026 tested EVs in the extreme cold to evaluate the impact on range and charging times of models including the Kia EV4 and MG 6S EV ...

CVS Health is effectively telling Tennessee lawmakers, “Nice pharmacy bill you’ve got there. Shame if something happened to 134 stores.” The company says a proposal targeting pharmacy benefit managers ...

The U.S. Food and Drug Administration on Wednesday approved Eton Pharmaceuticals' first-of-its-kind liquid therapy for a rare hormonal disorder, offering a more precise dosing option for families ...

Major League Baseball can’t implement the Automated Ball-Strike (ABS) Challenge System this season without knowing every hitter’s precise height, right down to the millimeter. So, like a flashback to ...

Explore the benefits and drawbacks of A1C and time in range for diabetes management, including why experts use both metrics to track blood sugar health effectively.